Milestone Phamaceuticals

[Milestone Phamaceuticals @MIST_Milestone]

We’re looking forward to joining Cantor Fitzgerald at their upcoming Global Healthcare Conference.

Discover more about our work to advance innovative cardiovascular medicines: https://t.co/EQWLA08sbu

#MIST #InvestorRelations #IR

[Milestone Phamaceuticals @MIST_Milestone]

Our President and CEO, Joe Oliveto will participate in a fireside chat today at the @Wells Fargo21st Annual #Healthcare Conference.

Webcast link: https://t.co/a9eYic6lgU

#MIST #Biotech #Cardiology #Investing

[Milestone Phamaceuticals @MIST_Milestone]

NEWS UPDATE! China’s National Medical Products Administration (NMPA) has approved etripamil for adults with paroxysmal supraventricular tachycardia (#PSVT) in China.

Learn more in the press release: https://t.co/4rA3xawA7H

[Milestone Phamaceuticals @MIST_Milestone]

September will be an exciting month for Milestone Pharmaceuticals!

We look forward to engaging with our investor community at upcoming conferences, sharing our recent progress in the cardiovascular space and discussing the opportunities ahead.

Learn more here: https://t.co/cy8hXJtQJZ

#InvestorRelations #Cardiology

[Milestone Phamaceuticals @MIST_Milestone]

Today we announced findings from a longitudinal survey study describing how paroxysmal supraventricular tachycardia (#PSVT) affects patients’ daily lives and quality of life in the periods between episodes.

Learn more: https://t.co/wbnWakOJ48

Thank you Dr. Sean Pokorney and @DCRINews for your contributions to this important field of research!

#ESCCongress

[Milestone Phamaceuticals @MIST_Milestone]

We are proud to announce our new partnership with @MedAxiom, an @ACCinTouch Company, the cardiovascular community's premier source for organizational performance solutions.

[MedAxiom @MedAxiom]

We’re excited to welcome @MIST_Milestone as a new MedAxiom industry partner.

Together, we’re connecting cardiovascular leaders with industry innovation to help advance care for people living with heart rhythm disorders.

Learn more: https://t.co/J6BcFBeJOT

#MedAxiom #Cardiology #CardiovascularCare

[Milestone Phamaceuticals @MIST_Milestone]

NEWS UPDATE! @mist_milestone is excited to announce that the first patient has been enrolled in our ReVeRA-301 Phase 3 pivotal trial.

Learn more: https://t.co/i4bqDAcSfa

[Milestone Phamaceuticals @MIST_Milestone]

Today we're announcing our Q2 2026 financial results and providing a corporate update. Join us for our conference call and webcast at 8:30AM ET

Details & webcast: https://t.co/n3OgzENcoD

Learn more: https://t.co/l0u3BzkpEA

[Milestone Phamaceuticals @MIST_Milestone]

We're honored to have been nominated for the prestigious @PrixGalien Awards! This recognition reflects our commitment to advancing innovative cardiovascular therapies and the dedication of our team, collaborators, and partners. Learn more: https://t.co/5nRMH6HHj7